Subscription is FREE for qualified healthcare professionals in the US.
14 Articles in Volume 18, Issue #2
Ask the Expert: Is there evidence to prescribe cyclobenzaprine long-term?
Challenging the Chronic Pain Personality Profile
Designer Peptide May Prevent Chemo-Induced Neuropathy
Inside the Cancer Pain Research Consortium
Intrathecal Drug Therapy for Cancer-Related Pain
Managing Cancer Pain in an Era of Modern Oncology
Mapping Complex Pain: A Case Study
Medication Overuse Headache: Inaccurate and Overdiagnosed
Pain and Fall Risk in the Elderly
Reporting Quality of Care in Cancer Pain Management
Sharing the Risk: An Update to DEA & Doctors Working Together
The Intensifying Conflict Between Opioid Control and Pain Control
Two Mobile Apps Aim to Target Patient Compliance & Safety
Why Prescribers Need to Adopt Abuse-Deterrent Opioids

Intrathecal Drug Therapy for Cancer-Related Pain

An update on key considerations for oncology and pain practitioners
Page 1 of 2


Intrathecal drug delivery, or intrathecal therapy (ITT), has been a mainstay for the management of severe pain recalcitrant to systemic pain treatments in the oncology population. While this therapy is well accepted in the literature, there are still barriers to its implementation in patients with cancer. With enhanced education of advanced practice providers in this field, it is hoped that access to the therapy for the management of cancer pain will increase. Herein, the authors discuss general indications and patient selection for ITT, with a discussion on management of the infusion, as well as post-procedure concerns.

Cancer pain remains undertreated, and a significant number of patients with cancer die while suffering from severe untreated pain every year. In addition, it is estimated that at least 1.7 million new cases of cancer were diagnosed in the United States in 2017.1 The number of individuals living beyond a cancer diagnosis reached nearly 14.5 million in 2014 and is expected to rise to almost 19 million by 2024.1

With an increasing survival rate for oncologic patients, the prevalence of cancer pain is also rising. Pain occurs in 67% of patients with metastatic cancer and is the most prevalent symptom of patients presenting to palliative care clinics.2,3 While the vast majority of chronic cancer pain may be managed with pharmacologic therapies, many patients do not achieve adequate analgesia despite the availability of many regimens.4 Treatment of cancer-related pain has shifted toward chronic pain management strategies, especially among cancer survivors. Intrathecal drug delivery may provide an alternate route of administration for analgesics, which may improve pain relief and side effect management.5

Images courtesy Medtronic and FlowonixImages courtesy Medtronic and Flowonix


Patient Selection for ITT

As certain cancers are associated with higher incidence of pain, patient selection for ITT is extremely important to establish who may benefit from intrathecal pump placement.

These factors include:

  • patient diagnosis and expected survival time
  • previous opioid history
  • type and location of pain
  • catheter location
  • support system
  • ability to adhere to ITT regimen
  • psychological and cognitive status.

Therefore, before implantation, it is essential to have a clear diagnosis, a comprehensive physical exam and psychological evaluation (this may be voluntary for cancer pain patients). Once it is established that a patient may benefit from ITT, it is essential to receive proper treatment for conditions such as psychiatric disorders and psychosocial issues that could negatively impact treatment outcomes. It may also be helpful for patients with cancer-related pain to undergo counseling to address any existential or spiritual concerns. In addition, all patients should have realistic expectations of ITT on pain relief and understand how it may impact their daily life.2

Typically, ITT is recommended after initial attempts of pain control are not achieved with systemic pain regimens, such as opioid therapy. Intrathecal drug delivery may be considered, if and when, its benefits are consistent with the patient and family’s goals of care. Intrathecal drug delivery involves the infusion of highly concentrated solutions into the intrathecal space. The medication interrupts pain signals to the brain by blocking the transmission (local anesthetic) or facilitating the modulation of the pain signal (opioid) in the spine. When delivered intrathecally, opioids and adjunct analgesics may provide greater pain relief at significantly lower doses with fewer side effects.

Medication Choices

The United States Food and Drug Administration (FDA) approves spinal delivery medications in the same way it approves other medication—that is, after extensive clinical trials demonstrate safety and efficacy. Currently, only three medications have been approved by FDA for use via the intrathecal route: morphine, ziconotide, and baclofen.7 The use of other agents is common among pain practitioners who manage intrathecal pumps, and recommendations from the Polyanalgesic Consensus Conference 2017 of such agents provided guidance on safe practice and patient safety.7 Hydromorphone, fentanyl, and sufentanil are not FDA approved for spinal use, but are commonly used by practitioners for intrathecal infusions.

Side Effects

Despite its relative small dosages compared to oral or parenteral opioids, escalating doses of intrathecal opioids may still lead to undesirable side effects, including pruritus, nausea and vomiting, constipation, respiratory depression, sexual dysfunction, hyperalgesia, urinary retention, and sedation.8 For many patients who are taking high doses of intrathecal opioids and still experience refractory pain, adding a local anesthetic may significantly improve their symptoms, pain scores, activity level, and quality of life.9 Local anesthetics have been used for many years in patients with severe and intractable pain to offer more effective pain control without necessitating very high dosages of opioids. In fact, survey data suggest that almost 20% of intrathecal pump patients received local anesthetics as early as 1996.10


Bupivacaine is FDA approved for continuous epidural infusion but is commonly used, intrathecally, in combination with opioids for the treatment of cancer pain. Bupivacaine is a lipophilic sodium channel blocker that preferentially blocks nerve fibers in pain conduction. However, at higher dosages, bupivacaine may also block nerve fibers involved in sensation to light touch and motor function.11 While many researchers have suggested that intrathecal bupivacaine is efficacious when added to opioid medications, to date, there are few guidelines to suggest the safe starting dose of bupivacaine in intrathecal pumps, or the safe rate at which to up-titrate the dosage.12

Doses are typically titrated up or down in accordance to the individual patient, however, there is a gap in the literature in regards to how much and how quickly to titrate. Further studies are needed to elucidate the safe starting dose of bupivacaine, the safe rate of up-titration, and to control for the concurrently used opioids and other adjuvants such as clonidine.

Combinations with Clonidine & Opioids

Drug combinations in spinal infusions are often necessary for effective treatment of neuropathic and mixed pain disorders. The use of other agents is common among pain practitioners who manage intrathecal pumps, and discussions and recommendations for the safety of such agents are included in the Polyanalgesic Consensus Conference.7

Last updated on: April 6, 2018
Continue Reading:
Managing Cancer Pain in an Era of Modern Oncology